The Medicines Co., of Parsippany, N.J., reported fourth-quarter and full-year earnings that included worldwide net revenue of $67.2 million for the fourth quarter of 2015 compared to $173.1 million in the fourth quarter of 2014, with thrombin inhibitor Angiomax/Angiox (bivalirudin) net product sales at $23.2 million in the fourth quarter of 2015 compared to $165.9 million in the fourth quarter of 2014.